Studies and Science
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain
By Dr. Erin E Krebs, MD, MPH and Amy Gravely, MA; Sean Nugent. BA; Agnes C Jensen, MPH; Beth DeRonne, PharmO; Elizabeth S. Goldsmith, MD, MS; Kurt Kroenke, MO; Matthew J. Bair; Siamak Noorbaloochi. PhD
*American Medical Association*
Role of Low-Level Laser Therapy in Neurorehabilitation (Transcranial)
CELLULAR AND MOLECULAR MECHANISMS OF LLLT for:
STROKE
TRAUMATIC BRAIN INJURY
DEGENERATIVE CENTRAL NERVOUS SYSTEM DISEASE
SPINAL CORD INJURY
PERIPHERAL NERVE
NPF - Effects of Low-Level Laser Therapy in Autism Spectrum Disorder
Effects of Low-Level Laser Therapy in Autism Spectrum Disorder_full
The Use of Low Level Laser Therapy (LLLT )For Musculoskeletal Pain
What is LLLT?
History of LLLT
Mechanisms of LLLT
LLLT in the treatment of pain
- PubMed -
The need for other pain treatment forms
Article on how dangerous common Pain Meds are and the link of higher risk of heart problem.
Denise H. Hawkins, M. Tech and Heidi Abrahamse, PhD - Faculty of Health, University of Johannesburg,
The Role of Laser Fluence in Cell Viability, Proliferation, and Membrane Integrity of Wounded Human Skin Fibroblasts Following Helium-Neon Laser Irradiation
Chiros and other Doctors - Lecture and articles
Dr. Silverman - Violet Laser (Florida Chiropractic Association)
The gut-brain axis in health and disease
DR. Kerry Zang, DPM - Foot and Ankle Pathology
Inflammatory & Degenerative Processes in Tendons, Capsules & Fascia, Tendonitis and
Peripheral Neuropathy.
Pain Management: Orthopedics & Sports medicine by Dr. Robert Sullivan
A modern evidence based, none pharmaceutical approach using 635nm low level laser device
A double blind randomised controlled study on Perhiperal Neuropathy in Diabetes
A double blind randomised controlled study to investigate the effects of Low Level Laser Therapy on Perhiperal Neuropathy in Diabetes
Dr. Robert Sullivan.
Dr. Huang - Biphasic Dose Response in LLLT (Harvard)
Refers to over 100 level III randomized clinical studies.
Dr. Richard Silverstein, DPM "Low Level Laser Technology and Your Practice"
It’s a great time to incorporate this technology into clinical practice -
"We have all jumped onto that one risky product or service thinking it would be a great idea but never really implemented it for one reason or another."
By Richard Silverstein, DPM
Dr. Dan Murphy - Lecture by Ryan Maloney, wavelengths
Low Level Laser Therapy
Electron Volt Theory
Synopsis of a Lecture by Ryan Maloney, explaning: Wavelengths
Dr. Dan Murphy DC, DABCO - Practical PAIN MANAGEM ENT, October 2007
"Conversely, anything that improves the flow of electrons through the respiratory chain will increase the production of ATP while reducing the generation of free radicals. This is the key to low-level laser therapy.
Broshyrer, prislista och media
Prislista handhållen laser 2019 - "Framtiden ser ljus ut!"
De senaste 30 årens forskning på fotonenergi och celler har idag lett till 16 stycken FDA-godkännanden av vår tillverkare Erchonia i USA. Området det forskas mest på just nu är hjärnhälsa. Den senaste kvadrupelblinda studien för nästa FDA-godkännande, påvisar en halvering av autismspektrum (NPF) inom åtta veckors behandling. Idag behandlas autism, depression, parkinson, smärta, neuropati, inflammationer, ische-miska sår och övervik
Flyer: FX-635
Världens enda FDA-godkända lågenergilaser för kronisk ländryggssmärta och plantarfasciit
Laser facts, LLLT, Class 2, Class IV and FDA
Hot vs. Cold Lasers - How They Work
A hot topic within the profession
is the use of cold lasers.
FDA - 510(k) Summary for FX635
The Erchonia® FX-635 is low level laser system that uses three semi-conductor diodes (visible red-light) 630nm to 650nm. A variable hertz device. The FX-635 has been classified by the FDA/EC as a Class II/IIa device and a Class II/2 Laser. The FX-635 is indicated for use as an adjunct to provide relief of minor chronic low back pain of musculoskeletal origin and reducing chronic heel pain arising from plantar fasciitis
FDA Market Clears Erchonia’s FX 635 Laser for Chronic Low Back Pain
First and Only FDA Market Cleared Low-Level Laser Treatment Option. The success criteria were defined as a minimum of a 30% decrease in chronic low back pain and 35% of patients in the treated group would experience the minimum pain reduction compared to the placebo group. Overall, 72% of patients met the success criteria.